Neuraminidase inhibitors: Who, when, where?

Clinical Microbiology and Infection

Volumn 21, Issue 3, 2015, Pages 222-225

  Nguyen Van Tam, J S ^a   Venkatesan, S ^a   Muthuri, S G ^a   Myles, P R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antivirals; Influenza; Inhibitors; Neuraminidase; Treatment

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE SEVERITY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFLUENZA A (H1N1); LENGTH OF STAY; META ANALYSIS; MORTALITY; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; VIRUS VIRULENCE; ANTAGONISTS AND INHIBITORS; EVIDENCE BASED MEDICINE; INFLUENZA A VIRUS; INFLUENZA, HUMAN; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; TREATMENT OUTCOME;

EID: 84933514155     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.11.020     Document Type: Review

References (21)

1. Mast E.E., Harmon M.W., Gravenstein S., Wu S.P., Arden N.H., Circo R., et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991, 134:988-997.
2. Englund J.A., Champlin R.E., Wyde P.R., Kantarjian H., Atmar R.L., Tarrand J., et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998, 26:1418-1424.
3. Summary of Product Characteristics (SPC), Lysovir 100mg capsules (amantadine hydrochloride). Available at: . [last accessed 31.10.14]. http://www.medicines.org.uk/emc/medicine/2496.
4. Summary of Product Characteristics (SPC), Tamiflu 75mg hard capsules (oseltamivir phosphate). Available at: . [last accessed 31.10.14]. http://www.medicines.org.uk/emc/medicine/10446.
5. Kaiser L., Wat C., Mills T., Mahoney P., Ward P., Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003, 163:1667-1672.
6. Peltola V., Reunanen T., Ziegler T., Silvennoinen H., Heikkinen T. Accuracy of clinical diagnosis of influenza in outpatient children. Clin Infect Dis 2005, 41:1198-1200.
7. Mulpuru S., Roth V.R., Lawrence N., Forster A.J. Influenza infection screening tools fail to accurately predict influenza status for patients during pandemic H1N1 influenza season. Can Respir J 2013, 20:e55-e59.
8. Mahony A.A., Cheng A.C., Olsen K.L., Aboltins C.A., Black J.F., Johnson P.D., et al. Diagnosing swine flu: the inaccuracy of case definitions during the 2009 pandemic, an attempt at refinement, and the implications for future planning. Influenza Other Respir Virus. 2013, 7:403-409.
9. National Institute for Health and Care Excellence. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168). Available at: . [last accessed 31.10.14]. http://www.nice.org.uk/guidance/TA168.
10. World Health Organization. Responding to the avian influenza pandemic threat. Recommended strategic actions. Available at: . [last accessed 31.10.14]. http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_05_8-EN.pdf.
11. Jefferson T., Jones M.A., Doshi P., Del Mar C.B., Hama R., Thompson M.J., et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children (Review). Cochrane Database Syst Rev 2014, 4:CD008965. Available at:, [last accessed 30.10.14]. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008965.pub4/pdf.
12. Muthuri S.G., Venkatesan S., Myles P.R., Leonardi-Bee J., Al Khuwaitir T.S., Al Mamun A., et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014, 2:395-404.
13. Summary of Product Characteristics (SPC), Relenza 5mg inhalation powder (zanamivir). Available at: . [last accessed 31.10.14]. http://www.medicines.org.uk/emc/medicine/2608.
14. Dobson J., Whitley R.J., Pocock S., Monto A.S. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015, [Epub ahead of print]; avialable at: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2962449-1/abstract [last accessed: 30.01.2015].
15. Riley R.D., Lambert P.C., Abo-Zaid G. Meta-analysis of individual participant data: conduct, rationale and reporting. Br Med J 2010, 340:c221.
16. Muthuri S.G., Myles P.R., Venkatesan S., Leonardi-Bee J., Nguyen-Van-Tam J.S. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. JInfect Dis 2013, 207:553-563.
17. Okoli G.N., Sanders R.D., Myles P. Demystifying propensity scores. Br J Anaesth 2014, 112(1):13-15.
18. Lévesque L.E., Hanley J.A., Kezouh A., Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. Br Med J 2010, 340:b5087.
19. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008, 167:492-499.
20. Leonardi-Bee J., Venkatesan S., Muthuri S.G., Nguyen-Van-Tam J.S., Myles P.R. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med 2014, 2:e10-12. PRIDE Research Consortium.
21. Gupta R.K., George R., Nguyen-Van-Tam J.S. Bacterial pneumonia and pandemic influenza planning. Emerg Infect Dis 2008, 14:1187-1192.